COMPANY PROFILE

Perspectum

Explore full profile

AI-powered software for non-invasive multi-organ diagnostics

Oxford, United KingdomFounded 2012Health Tech & Medtech

Valuation $100–250M Last recorded · 2023

Revenue $10–50M Latest reported FY

Headcount 100–500 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Perspectum

Perspectum is a precision health technology company that develops non-invasive medical imaging software to aid in the diagnosis and monitoring of various diseases. Founded in 2012 as a spin-out from the University of Oxford, the company was established by Dr. Rajarshi Banerjee, Professor Sir Michael Brady, and Dr. Matthew Robson. The foundation was based on research demonstrating how multiparametric Magnetic Resonance Imaging (MRI) could be used to assess patients with liver disease. Dr. Banerjee, the CEO, is a physician with a background in medicine from the University of Oxford and public health from the London School of Hygiene and Tropical Medicine. Sir Michael Brady, a co-founder, is a distinguished professor in oncological and information engineering at Oxford with extensive experience in AI, image analysis, and has founded several other medical imaging companies.

Read full description

The company's core business revolves around providing Software-as-a-Service (SaaS) diagnostic tools that enhance standard MRI scanners with AI-driven software to quantify organ health. This technology offers a non-invasive alternative to procedures like liver biopsies. Revenue is generated by providing these specialized diagnostic services to healthcare providers, such as hospitals and clinics, and through collaborations with pharmaceutical companies to support clinical trials with their imaging biomarkers. Perspectum's products are used by clinicians for diagnosis and treatment decision-making, and by researchers to accelerate studies on metabolic diseases, cancer, and other chronic conditions.

Perspectum's flagship product, LiverMultiScan, provides a quantitative assessment of the liver, measuring fat, iron, fibrosis, and inflammation to help diagnose and monitor chronic liver diseases like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company has received multiple FDA 510(k) clearances for its products, including LiverMultiScan, MRCP+ for advanced biliary visualization, Hepatica for surgical planning in liver cancer, and CoverScan for multi-organ assessment. CoverScan, for instance, provides a comprehensive evaluation of the heart, liver, lungs, kidneys, pancreas, and spleen in a single MRI scan. Perspectum has raised approximately $140 million in funding over several rounds, with its Series C funding led by Oppenheimer.

Source: Dealroom company data